Denmark: Sorensen named Hemab CEO in US as company secures US$55m Series A financing

Benny Sorensen has been appointed CEO of Hemab, a biotech company developing next generation therapeutics for serious underserved bleeding and thrombosis disorders. He will be based in the US. The move comes as Hemab closes a US$55m Series A financing, led by Novo Holdings, HealthCap and RA Capital Management. Proceeds will be used to progress…

You must be a HMI Subscriber to view this content.

Subscribe Now »